ABL1 anticorps

N° du produit ABIN967410

Cet anticorps anti-ABL1 est un anticorps Souris Monoclonal détectant ABL1 dans WB, IF et IP. Adapté pour Humain et Souris. Ce Primary Antibody a été cité dans 5+ publications.

Aperçu rapide pour ABL1 anticorps (ABIN967410)

Antigène: ABL1 (C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1))

Reactivité: Humain, Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp ABL1 est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF), Immunoprecipitation (IP)

Clone: 8E9

Détail du produit anti-ABL1 anticorps

Marque: BD Pharmingen™

Réactivité croisée: Souris

Attributs du produit: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: Recombinant Mouse Abl Gag Fusion Protein

Isotype: IgG1

Information d'application

Commentaires:

Related Products: ABIN967389

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store undiluted at 4° C.

Références pour anticorps anti-ABL1 (ABIN967410)

Guo, Lian, Xian, Lee, Deisseroth, Stass, Champlin, Talpaz, Wang, Arlinghaus: "BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy." dans: Blood, Vol. 83, Issue 12, pp. 3629-37, (1994) (PubMed).

Guo, Hirsch-Ginsberg, Xian, Stass, Champlin, Giralt, McCredie, Campbell, Arlinghaus: "Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia." dans: Hematologic pathology, Vol. 7, Issue 2, pp. 91-106, (1993) (PubMed).

Guo, Wang, Arlinghaus: "Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients." dans: Cancer research, Vol. 51, Issue 11, pp. 3048-51, (1991) (PubMed).

Wang: "Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids." dans: Oncogene research, Vol. 3, Issue 3, pp. 293-8, (1989) (PubMed).

Kipreos, Lee, Wang: "Isolation of temperature-sensitive tyrosine kinase mutants of v-abl oncogene by screening with antibodies for phosphotyrosine." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 84, Issue 5, pp. 1345-9, (1987) (PubMed).

Détails sur ABL1

Antigène: ABL1 (C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1))

Autre désignation: Abl

Sujet: The proto-oncogene c-abl was first isolated from the mouse genome as a gene with similarity to the v-abl oncogene of Abelson murine leukemia virus. The c-abl gene encodes a protein tyrosine kinase that is localized in the cytoplasm and nucleus. The c-abl protein shares several common features with other cytoplasmic tyrosine kinases, including the src-homology domains 2 (SH2) and 3 (SH3). The SH2 domain is believed to bind specifically to tyrosine residues of other proteins. The function of the SH3 domain is still unclear. Unique to the c-abl tyrosine kinase is a large C-terminal segment which seems to be essential for its biological function, since mice homozygous for a C-terminal deletion of c-abl have multiple defects at birth. The C-terminal fragment of c-abl contains a DNA-binding domain, and the DNA-binding affinity of this domain seems to be regulated by phosphorylation of critical serine/threonine residues. The c-abl proto-oncogene can be activated in a variety of ways. For example, in Philadelphia chromosome (Ph1)-positive leukemias the c-abl proto-oncogene on chromosome 9 becomes fused to the bcr gene on chromosome 22, and bcr-abl fusion proteins are produced. Ph1-positive cells express either the a-typical 210 kDa bcr-abl fusion protein or a smaller 185 kDa bcr-abl fusion protein. The bcr sequences activate the c-abl tyrosine kinase by deregulating its expression, and actin filament-binding function associated with c-abl is also activated. Expression of bcr-abl fusion proteins in vitro leads to transformation of pre-B lymphoid cells supporting their role as an oncogene. The phosphorylated form of c-abl is observed at ~145 kDa on SDS/PAGE. The 8E9 clone has been reported to react with an epitope in the tyrosine kinase domain of murine abl proteins [Wang et al.]. This antibody is routinely tested by western blot analysis.

Poids moléculaire: 145 kDa

Pathways: Apoptose, Regulation of Muscle Cell Differentiation, Platelet-derived growth Factor Receptor Signaling, Lipid Metabolism